Linezolid-induced hypoglycaemia in a patient with type 1 diabetes

Abstract

Linezolid is a relatively novel oxazolidinone and its use is currently limited to secondary care in the UK. It is a reversible, non-selective monoamine oxidase inhibitor, but at the doses used for antibacterial therapy it does not exert an anti-depressive effect. It has a potentially serious side effect profile and is monitored intensively by the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency. Herein we report the rarely recognised complication of linezolid-induced hypoglycaemia in a patient with type 1 diabetes.

Keywords

antibacterial hypoglycaemia linezolid oxazolidinone

Get full access to this article

View all access options for this article.

References

Boulton

Vileikyte

Ragnarson-Tennvall

Apelqvist

. The global burden of diabetic foot disease. Lancet 2005;366:1719-24.

Prompers

Huijberts

Schaper

. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia 2008;51:1826-34.

Vuorisalo

Venermo

Lepantalo

. Treatment of diabetic foot ulcers. J Cardiovasc Surg (Torino) 2009;50:275-91.

Lipsky

Berendt

Deery

. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.

Vinh

Rubinstein

. Linezolid: a review of safety and tolerability. J Infect 2009;59(suppl 1):S59-74.

MHRA. PIPERACILLIN/TAZOBACTAM 2G/0.25G AND 4G/0.5G POWDER FOR SOLUTION FOR INFUSION, PL 24598/0012 AND PL 24598/0019. London: Medicines and Healthcare products Regulatory Agency. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con134789.pdf (Accessed August 2012)

Datapharm Communications Ltd. Linezolid Summary of Product Characteristics (SPC). >Electronic Medicines Compendium. Leathehead: Datapharm Communications Ltd, 29 September 2010. http://www.medicines.org.uk/emc/medicine/9857/SPC/ (Accessed August 2012).

MHRA. Linezolid Drug Analysis Print. Medicines and Healthcare products Regulatory Agency website 2011 March 31 Available from: URL: http://www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_1343142299751.pdf

Bodnar

Starr

Halter

. Linezolid-associated hypoglycemia in a 64-year-old man with type 2 diabetes. Am J Geriatr Pharmacother 2011;9:88-92.

10.

Adnitt

. Monoamineoxidase inhibition and insulin sensitivity. J Endocrinol 1968;42:417-23.

11.

Cooper

Ashcroft

. Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs. Lancet 1966;1:407-9.

12.

McIntyre

Soczynska

Konarski

Kennedy

. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006;5:157-68.

13.

Drozak

Kozlowski

Doroszewska

. Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies. Chem Biol Interact 2007;170:162-76.

14.

Gaziano

Cincotta

O’Connor

. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-8.